Testing Spanish-language Genetic Literacy
Public ClinicalTrials.gov record NCT01610583. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Development of a Tool to Assess Spanish-Language Genetic Literacy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Background: * Health literacy means being able to understand basic health care information. This information can include drug labels and prescription instructions. It can also include doctor s instructions. Better health literacy can help improve a person s health outcomes. * Many minorities have low health literacy. Latinos in particular have both low health literacy and poor health outcomes. Language barriers such as poor reading skills can contribute to problems with health literacy. Researchers want to develop a new health literacy measuring tool. This tool will focus on genetic literacy, which involves understanding personal risk of health problems. The tool will be written in Spanish. The study will work with Spanish-speaking Latinos to develop and test this genetic literacy tool. Objectives: \- To develop a Spanish-language tool to study genetic literacy. Eligibility: \- Spanish-speaking Latino adults between 18 and 75 years of age. Design: * Participants will be screened with a brief interview. No personal samples will be needed. * Participants will complete the genetic literacy questionnaire. It will be given in Spanish. * The tool will ask about participants personal and family health history. It will also ask about their understanding of genetic terms and genetic testing. Other personal information, such as level of education, will be collected. * Participants will receive a gift card for completing the survey. * No treatment or genetic counseling will be provided as part of this study.
Study identification
- NCT ID
- NCT01610583
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 117 participants
Conditions and interventions
Conditions
Interventions
Not listed
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 23, 2012
- Primary completion
- Not listed
- Completion
- Feb 22, 2015
- Last update posted
- Dec 16, 2019
2012 – 2015
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| National Human Genome Research Institute (NHGRI), 9000 Rockville Pike | Bethesda | Maryland | 20892 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01610583, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 16, 2019 · Synced Sep 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01610583 live on ClinicalTrials.gov.